Peter Feinberg, a director at $IMRX, bought 20,000 shares of the company on 01-12-2026 for an estimated $86,904. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 17.3%. Following this trade, they now own 135,441 shares of this class of $IMRX stock.
$IMRX Insider Trading Activity
$IMRX insiders have traded $IMRX stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:
- PETER FEINBERG has made 4 purchases buying 40,000 shares for an estimated $225,559 and 0 sales.
- MICHAEL BOOKMAN (CHIEF LEGAL OFFICER, SECRETARY) purchased 1,020 shares for an estimated $6,966
- LEAH R NEUFELD (CHIEF PEOPLE OFFICER) purchased 800 shares for an estimated $5,103
- MALLORY MORALES (Chief Accounting Officer) purchased 300 shares for an estimated $1,917
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMRX Hedge Fund Activity
We have seen 54 institutional investors add shares of $IMRX stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 8,566,052 shares (+3876.0%) to their portfolio in Q3 2025, for an estimated $59,962,364
- SANOFI added 2,708,559 shares (+inf%) to their portfolio in Q3 2025, for an estimated $18,959,913
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,798,782 shares (+inf%) to their portfolio in Q3 2025, for an estimated $12,591,474
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,516,833 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,617,831
- VANGUARD GROUP INC added 1,358,322 shares (+128.5%) to their portfolio in Q3 2025, for an estimated $9,508,254
- LOGOS GLOBAL MANAGEMENT LP added 950,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,650,000
- CITADEL ADVISORS LLC added 943,144 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,602,008
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMRX Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 11/13/2025
- Leerink Partners issued a "Outperform" rating on 10/31/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/30/2025
- Oppenheimer issued a "Outperform" rating on 09/25/2025
- Needham issued a "Buy" rating on 09/15/2025
To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.
$IMRX Price Targets
Multiple analysts have issued price targets for $IMRX recently. We have seen 5 analysts offer price targets for $IMRX in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $20.0 on 11/13/2025
- Andrew Berens from Leerink Partners set a target price of $15.0 on 10/31/2025
- Ami Fadia from HC Wainwright & Co. set a target price of $11.0 on 09/30/2025
- Jay Olson from Oppenheimer set a target price of $30.0 on 09/25/2025
- Ami Fadia from Needham set a target price of $11.0 on 09/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
